A Phase II Study Of Perifosine (D-21266) In Patients With Previously Untreated Metastatic Or Locally Advanced Soft Tissue Sarcoma
Latest Information Update: 08 Aug 2023
Price :
$35 *
At a glance
- Drugs Perifosine (Primary)
- Indications Alveolar soft part sarcoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Neurofibrosarcoma; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Adverse reactions; Therapeutic Use
- 11 Aug 2009 Lead trial centre and lead investigators added as reported by ClinicalTrials.gov.
- 21 Mar 2006 Status changed from suspended to completed.
- 23 Sep 2005 New trial record.